Periodic Versus Continuous IV Iron Supplementation in HD Patients

Periodic Versus Continuous (at Every Session of Hemodialysis) iv Iron Supplementation in Chronic HD Patients

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02787824

Enrollment

Registered

2016-06-01

Start date

2016-05-31

Completion date

2016-10-31

Last updated

2017-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia of Chronic Kidney Disease

Keywords

iron deficiency, hemodialysis

Brief summary

The purpose of this study was to compare the efficacy of two regimens of intravenous iron sucrose \[continuous (in every hemodialysis session) versus intermittent (every 1-4 weeks)\] on the response of rHuEPO in the maintenance phase of its administration in hemodialysis patients.

Interventions

DRUGIron Sucrose Supplement

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Constant rHu-EPO and iron dose for at least 2 months before starting the study * Hemoglobin ≥ 8,5g/dl and \<12,5 g/dl * Ferritin \< 1000 mg/dl * TSAT \< 50% * CRP \< 5 mg/dl

Exclusion criteria

* Malignant tumor disease * Oral iron supplementation * Active bleeding issues * Surgical intervention within the last 8 weeks before study inclusion

Design outcomes

Primary

Measure	Time frame
Change of serum hemoglobin level (g/dl)	Month 0, 1, 2, 3, 4

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026